# Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT04673448** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Washington** · enrollment: 18 (actual)

## Conditions studied

- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- BRCA-Associated Malignant Neoplasm
- BRCA Hereditary Ovarian Carcinoma
- Metastatic BRCA Hereditary Breast Carcinoma
- Metastatic Breast Carcinoma
- Metastatic Fallopian Tube Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Ovarian Carcinoma
- Metastatic Pancreatic Carcinoma
- Metastatic Primary Peritoneal Carcinoma
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage III Fallopian Tube Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage III Primary Peritoneal Cancer AJCC v8
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8
- Unresectable Breast Carcinoma
- Unresectable Fallopian Tube Carcinoma
- Unresectable Malignant Solid Neoplasm
- Unresectable Ovarian Carcinoma
- Unresectable Pancreatic Carcinoma
- Unresectable Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** Dostarlimab
- **DRUG:** Niraparib
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT04673448
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-18
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-09-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04673448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04673448, "Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04673448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*